Tom Armistead

About the Author Tom Armistead

I'm a well-informed retail investor and post on SA in order to expose my thought process to critical examination and comment from readers. It makes me a better investor. I'm particularly proud of bullish macro articles posted in 2009 and later, in which I presented ideas that encouraged me to invest very profitably in a rising market. I also did articles on individual stocks, many of which contained insights not available elsewhere. Finally, I wrote a number of thoughtful articles critical of financialism and the lack of ethics on Wall Street. I do not post for compensation, as I am concerned that editorial policy encourages and pays a premium for articles that invite the reader to speculate on the short term movements of microcaps, penny stocks, and controversial issues. The best way for me to monetize my insights is to invest accordingly. As a retail investor, I don't give investment advice. I write about what I'm investing in, and the thought process involved in decision making and stock selection. Hopefully some of what I write is of benefit to others, by sharing my experience as I interpret it and helping them improve their investment thinking and process.

2014 Review And Plan For 2015

Early last year I published my starting portfolio, 19 picks with credentials as dividend growth stocks. Here’s a summary of how those stocks …

Why I Expect WTI To Go Back To $100

Given the extremely rapid movements in the price of oil (NYSEARCA:USO), and the confusing and contradictory commentary surrounding the issue, I felt it …

Server Acceleration: Altera FPGAs Vs. Nvidia GPUs

Altera (NASDAQ:ALTR) CEO John Daane has been talking about a potential growth opportunity arising from the use of FPGAs in server acceleration for …

Buybacks: Thoughts On The Analysis Of This Important Use Of Capital

Here ‘s a laundry list of factors to consider when evaluating buybacks: Price paid vs. a conservative estimate of value Historical buyback effectiveness: …

Is Pfizer Spending Enough On R&D?

R&D is a primary growth driver for pharmaceutical companies. Pfizer (NYSE:PFE) CEO Ian Read, newly appointed at the time, announced draconian cuts to …

Coca-Cola Has Growth, Margin And Capital Deployment Problems

The Coca-Cola Company (NYSE:KO) is caught in a squeeze between the need for more advertising and incentives to increase customer demand and a …

IBM: Taking A Hard Look At R&D

International Business Machines (NYSE:IBM) is cheap by many of the usual metrics, thanks to ongoing lack of revenue growth. The long-term potential created …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts